HemOnc Today New York

HemOnc Today New York

April 01, 2016
13 min watch
Save

VIDEO: Targeted therapy ‘not enough’ for long-term melanoma treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — Christian Blank, MD, PhD, staff member in medical oncology and group leader of the division of immunology at Netherlands Cancer Institute, reviewed new checkpoint targets during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.

Evidence suggests checkpoint modulation will be the backbone of melanoma therapy, Blank said.

“We have treated a lot of patients with immunotherapy and we have treated a lot of patients with targeted therapy,” Blank said. “I am convinced that, for long-term benefit, we need immunotherapy.”